RT Journal Article
SR Electronic
T1 Delineation of the infrequent mosaicism of <em>KRAS</em> mutational status in metastatic colorectal adenocarcinomas
JF Journal of Clinical Pathology
JO J Clin Pathol
FD BMJ Publishing Group Ltd and Association of Clinical Pathologists
SP 466
OP 469
DO 10.1136/jclinpath-2011-200608
VO 65
IS 5
A1 Bossard, Céline
A1 Küry, Sébastien
A1 Jamet, Philippe
A1 Senellart, Hélène
A1 Airaud, Fabrice
A1 Ramée, Jean-François
A1 Bézieau, Stéphane
A1 Matysiak-Budnik, Tamara
A1 Laboisse, Christian L
A1 Mosnier, Jean-François
YR 2012
UL http://jcp.bmj.com/content/65/5/466.abstract
AB This study addresses the extent of the heterogeneity of KRAS status, present in a minority of metastatic colorectal carcinomas (mCRCs), on the basis of a thorough analysis of surgical resection specimens. Eighteen patients with mCRC were included. KRAS mutations (exon 2, codons 12 and 13) were determined using PCR and subsequent direct sequencing. This analysis included primary tumours (n=21), synchronous (n=10) and metachronous (n=18) matched metastases, and pelvic recurrence (n=1). Heterogeneity of KRAS status consisted in KRAS mutated in (i) the primary tumour but not in its synchronous metastasis, (ii) the metastasis but not in the primary tumour, (iii) the pelvic recurrence but not in the primary tumour, (iiii) some metastases and not in others from the same patient. Finally, the KRAS status varied among different areas of the same metastatic focus. This study defines the concept of KRAS mosaicism that affects a minority of mCRCs.